Nanjing Vazyme Biotech Co Ltd
SSE:688105
Intrinsic Value
Nanjing Vazyme Biotech Co., Ltd. engages in the research and development, and production of antibody drugs. [ Read More ]
The intrinsic value of one Nanjing Vazyme Biotech Co Ltd stock under the Base Case scenario is 17.68 CNY. Compared to the current market price of 27.67 CNY, Nanjing Vazyme Biotech Co Ltd is Overvalued by 36%.
Valuation Backtest
Nanjing Vazyme Biotech Co Ltd
Run backtest to discover the historical profit from buying and selling Nanjing Vazyme Biotech Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Nanjing Vazyme Biotech Co Ltd
| Current Assets | 4.3B |
| Cash & Short-Term Investments | 3.5B |
| Receivables | 300.7m |
| Other Current Assets | 480.2m |
| Non-Current Assets | 1.5B |
| Long-Term Investments | 22.3m |
| PP&E | 735.2m |
| Intangibles | 229.1m |
| Other Non-Current Assets | 473.3m |
| Current Liabilities | 1.5B |
| Accounts Payable | 152.1m |
| Accrued Liabilities | 71.2m |
| Short-Term Debt | 1.2B |
| Other Current Liabilities | 147.1m |
| Non-Current Liabilities | 190.6m |
| Long-Term Debt | 107.7m |
| Other Non-Current Liabilities | 82.9m |
Earnings Waterfall
Nanjing Vazyme Biotech Co Ltd
|
Revenue
|
2.1B
CNY
|
|
Cost of Revenue
|
-749.5m
CNY
|
|
Gross Profit
|
1.4B
CNY
|
|
Operating Expenses
|
-1.7B
CNY
|
|
Operating Income
|
-316.5m
CNY
|
|
Other Expenses
|
84.6m
CNY
|
|
Net Income
|
-231.9m
CNY
|
Free Cash Flow Analysis
Nanjing Vazyme Biotech Co Ltd
Profitability Score
Profitability Due Diligence
Nanjing Vazyme Biotech Co Ltd's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Nanjing Vazyme Biotech Co Ltd's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Nanjing Vazyme Biotech Co Ltd's solvency score is 76/100. The higher the solvency score, the more solvent the company is.
Score
Nanjing Vazyme Biotech Co Ltd's solvency score is 76/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Nanjing Vazyme Biotech Co Ltd
According to Wall Street analysts, the average 1-year price target for Nanjing Vazyme Biotech Co Ltd is 43.72 CNY with a low forecast of 36.08 CNY and a high forecast of 52.5 CNY.
Shareholder Return
Price
Nanjing Vazyme Biotech Co Ltd
| Average Annual Return | -12.85% |
| Standard Deviation of Annual Returns | 46.82% |
| Max Drawdown | -85% |
| Market Capitalization | 11.1B CNY |
| Shares Outstanding | 400 010 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Nanjing Vazyme Biotech Co., Ltd. engages in the research and development, and production of antibody drugs. The company is headquartered in Nanjing, Jiangsu and currently employs 1,409 full-time employees. The company went IPO on 2021-11-15. The firm's main business is the technology research and development and product development of functional proteins such as enzymes, antigens, antibodies, and polymer organic materials. The firm's products include polymerase chain reaction (PCR), reverse transcription, gene sequencing series and other biological reagent products, quantum dot immunofluorescence reagents, latex enhanced immune turbidity reagents and colloidal gold immunochromatography reagents and other point-of-care testing (POCT) Diagnostic reagents and instruments.
Contact
IPO
Employees
Officers
The intrinsic value of one Nanjing Vazyme Biotech Co Ltd stock under the Base Case scenario is 17.68 CNY.
Compared to the current market price of 27.67 CNY, Nanjing Vazyme Biotech Co Ltd is Overvalued by 36%.
You don't have any saved screeners yet
